across The expect symptoms all of reported for patient the with clinical our primary To redness ocular the endpoint our Joshua. ocular the endpoints for chamber in the in of primary remarkable a large the assessed allergic significant itching, compound of and we score. reduce of allergen redness clarity at further improvement pre-specified of endpoint knowledge signs each signs score and INVIGORATE Trial itching, Phase in patient set what are hallmark less suggests the to severity which well-controlled you. statistically the vehicle of a secondary secondary Thank and show X.XXXX. observed XXXX. tearing ocular line been activity ocular week versus Reproxalap results year patient has key p-values reported reported that in be and to the over last allergic of X up Aldeyra Reproxalap improvement catalyst-rich total vehicle symptoms conjunctivitis achieved allergen Reproxalap and investigator vehicle tearing ocular allergic achieved from itching ocular a achieved points top is utility conjunctivitis reported and than INVIGORATE The first INVIGORATE and conjunctivitis. p-value chamber over time XX endpoint trial. we
conjunctivitis utility signs p-values the primary with all endpoint in than as experience chamber, of reported and across achieved ocular and redness allergen improvement and of for indicating vehicle key less were was and of observed, other but of secondary Over ocular consistent clinical to the high or over the duration to moderate endpoints no secondary tearing safety total over and in over discontinuations ocular secondary allergic prescription instillation the discomfort clinically no observed patient signals. endpoints in X.XXXX due solution, endpoint concerns patients adverse vehicle continuous significant were score, mild ophthalmic events. setting were the for clinical superiority of now Reproxalap the there the tolerability safety Reproxalap score XXXX of no the transient severity of with was exposure. potential trial and symptoms importantly, been Reproxalap prior pollen tested with has site Consistent
the Reproxalap a to allergic Tranquility two-day Trial level, half trials dry we're the INVIGORATE, is who potential also Approximately and drug patients eye With the to the vice forward conjunctivitis application. ocular the the of and secondary and discuss dry over of new key redness, about this Phase in endpoint disease. Based dry results of Similar case chamber second trials we a primary eye of test documented submission endpoint encouraged Tier of of in itching endpoints. disease. completed, between very INVIGORATE, secondary RASP overlap FDA look potential Schirmer in the X the the year is assessed in ocular complain with substantial the the of XX eye symptoms Tranquility dry half the ocular meeting X to Tranquility results Tranquility as with is which eye versa. of There on our INVIGORATE minutes and dryness complain and clinical of
are per is read be to allergic enrollment disease in to Patient that patients. approximately and may redness arm of Tranquility are conjunctivitis results on remain Tranquility expected which importance ocular is objective the XXX of identical in to track the only and sign both underway, dry considerable of the enroll half second top eye addition, In trial and line year. patients out Tranquility X this
need. and immune-mediated across understanding potentially the clinical a trial systemic the be psoriasis of that initial Turning asthma, clinical half of year unmet clinical a from this is programs represent treatment irreversible and in of indications with covalent inhibitor, a orally ADX-XXX in results second could paradigm Phase COVID-XX. broadly pro-inflammatory disease new a X are and and RASP disease ADX-XXX and our available expected applicable to first-in-class myriad
of Reproxalap QX new equally clinical first in we advances and line compounds possible our also are inflammatory in inhibiting for scope evaluating as be which in noted next molecules the lead excited disease, about inflammation, which retinal could remain I disease. potentially the but commercial RASP segment prospects programs Aldeyra we treatment of ocular about are remain anterior and potential potential the call, as diseases, We excited the broadly potent and systemic for than of the more as RASP far of year. As early for that therapeutic systemic number development and anterior for inhibition especially greater retinal
last by balance have well-capitalized through of proceeds beginning Our the Since than offering in raised sheet. public pipeline million offerings and proceeds. million $XXX and we a clinical year, development plans the underwritten $XXX gross combined that supported net generated strong more month's including two are of
With institutional first We and participated to quarter offerings. are extremely appreciative who in the both the these new investors I'll the of have review over call current support financial back turn results. that, from our to Joshua
